RELAY, Erlotinib Plus Ramucirumab in Untreated, -Mutated, Metastatic NSCLC: Outcomes by Exon 19 Deletion Variants.

INTRODUCTION

gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients with untreated advanced NSCLC and an activating mutation. This exploratory analysis evaluated potential associations between exon 19 deletion (ex19del) variants and clinical outcomes.

METHODS

Patients (N = 449) were randomized (1:1) to RAM plus ERL or PBO plus ERL. Plasma samples were collected at baseline, on treatment, and at 30-day post-study treatment discontinuation follow-up. Baseline and treatment-emergent gene alterations were investigated by Guardant360 next-generation sequencing. Patients with a valid baseline plasma sample and ex19del were included (RAM + ERL, n = 62; PBO + ERL, n = 72).

RESULTS

The most common ex19del variant was E746_A750del (67.2%); E746 deletions (E746del) occurred more frequently than L747 deletions (74.6% versus 25.4%, respectively). mutations were the most frequently co-occurring baseline gene alterations. With treatment arms combined, median PFS was 18.0 months versus 12.5 months for patients with uncommon (non-E746_A750del, n = 44) versus common (E746_A750del, n = 90) ex19del variants (hazard ratio [HR] = 1.657 [95% confidence interval or CI:1.044-2.630]). Median PFS was longer with RAM plus ERL versus PBO plus ERL for patients with the common (15.2 versus 9.9 mo; HR = 0.564 [95% CI: 0.344-0.926]) and E746del (15.4 versus 9.9 mo; HR = 0.587 [95% CI: 0.363-0.951]) variants. Treatment-emergent post-progression T790M rates were higher in the common versus uncommon and E746del versus L747 deletion subgroups.

CONCLUSIONS

RAM plus ERL provides benefit and improves treatment outcomes for patients with metastatic NSCLC with ex19del variants.